0.02AUD
5.21 MAUD
502.55 MAUD
248.84 M
About TELIX PHARMACEUTICALS LIMITED
Sector
Industry
CEO
Christian P. Behrenbruch
Website
Headquarters
Melbourne
Founded
2017
ISIN
AU000000TLX2
FIGI
BBG00HZHXWN4
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialisation. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TX250, TX591, and TX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TLX is 13.61 AUD — it has decreased by 0.80% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange TELIX PHARMACEUTICALS LIMITED stocks are traded under the ticker TLX.
TELIX PHARMACEUTICALS LIMITED is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
TLX stock is 4.09% volatile and has beta coefficient of 1.27. Check out the list of the most volatile stocks — is TELIX PHARMACEUTICALS LIMITED there?
One year price forecast for TELIX PHARMACEUTICALS LIMITED has a max estimate of 19.30 AUD and a min estimate of 13.52 AUD.
TLX earnings for the last quarter are −0.05 AUD per share, whereas the estimation was 0.06 AUD resulting in a −181.00% surprise. The estimated earnings for the next quarter are 0.07 AUD per share. See more details about TELIX PHARMACEUTICALS LIMITED earnings.
TELIX PHARMACEUTICALS LIMITED revenue for the last quarter amounts to 220.83 M AUD despite the estimated figure of 220.53 M AUD. In the next quarter revenue is expected to reach 280.18 M AUD.
Yes, you can track TELIX PHARMACEUTICALS LIMITED financials in yearly and quarterly reports right on TradingView.
TLX stock has risen by 7.17% compared to the previous week, the month change is a 8.36% rise, over the last year TELIX PHARMACEUTICALS LIMITED has showed a 46.19% increase.
TLX net income for the last quarter is 19.53 M AUD, while the quarter before that showed −14.32 M AUD of net income which accounts for 236.39% change. Track more TELIX PHARMACEUTICALS LIMITED financial stats to get the full picture.
Today TELIX PHARMACEUTICALS LIMITED has the market capitalization of 4.53 B, it has decreased by 0.56% over the last week.
No, TLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TELIX PHARMACEUTICALS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TELIX PHARMACEUTICALS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TELIX PHARMACEUTICALS LIMITED stock shows the buy signal. See more of TELIX PHARMACEUTICALS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TELIX PHARMACEUTICALS LIMITED future price: according to them, TLX price has a max estimate of 19.30 AUD and a min estimate of 13.52 AUD. Read a more detailed TELIX PHARMACEUTICALS LIMITED forecast: see what analysts think of TELIX PHARMACEUTICALS LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TELIX PHARMACEUTICALS LIMITED EBITDA is 58.44 M AUD, and current EBITDA margin is 11.63%. See more stats in TELIX PHARMACEUTICALS LIMITED financial statements.